UnitedHealth’s share price traced a steep descent through 2025, collapsing to five-year lows of $234.60 in August as selling pressure overwhelmed sentiment. Since then, the stock has staged a measured recovery, rebounding nearly 46.7% from those depths, though it remains down about 34% over the past year.UnitedHealthcare forms the foundation, providing health insurance coverage to millions and delivering scale and stable revenue. Optum complements this with growth-driven capabilities across healthcare servi ...

Core Insights - Kforce Inc. has experienced declining earnings for three consecutive years due to a slowing job market, but there are signs that the worst may be over for the company, which specializes in technology, finance, and accounting staffing services [1] Financial Performance - In Q3 2025, Kforce reported earnings of $0.63, beating the Zacks Consensus by $0.06, marking the first earnings surprise after two consecutive misses [2] - Revenue for the quarter decreased by 5.9% year-over-year to $332.6 million and also saw a slight decline of 0.5% quarter-over-quarter [2] - The Technology and Finance and Accounting segments showed better-than-expected results, with the Finance and Accounting business growing 6.9% sequentially [3] Analyst Outlook - Analysts are optimistic about Kforce's prospects heading into 2026, with two earnings estimates revised higher for both 2025 and 2026 in the last 60 days [4] - The 2025 Zacks Consensus estimate is now $2.13, reflecting a decline of 20.5% from the previous year, while the 2026 estimate is projected at $2.28, indicating a potential earnings growth of 7% [4][5] Valuation Metrics - Kforce is currently trading at a forward P/E ratio of 14.7, which is considered attractive for value investors [6][9] - The company has a price-to-sales (P/S) ratio of 0.4, suggesting that investors are getting $1 of sales for just $0.40 [11] - Kforce is also shareholder-friendly, with a dividend yield of 5% and a stock repurchase plan expanded to $100 million [11] Market Position - The staffing industry has faced challenges in recent years, placing Kforce in the bottom 5% of all Zacks Rank industries [11] - Despite the downturn, Kforce is viewed as a potential turnaround story within the staffing sector [12]

Accenture plc (NYSE:ACN) is among the most undervalued tech giants to buy according to hedge funds. As of December 26, Accenture plc (NYSE:ACN) has a rating of ‘Buy’ or equivalent from slightly more than half of the analysts covering the stock. While the target price ranges from $205 to $330, the median target of $300 implies an upside potential of 11.12%. On December 19, Surinder Thind, an analyst at Jefferies, reaffirmed a ‘Hold’ rating on the stock, with a price target of $270. Kevin McVeigh from UBS, ...

Unusual trading halt and record volume spotlight rising volatility risks for U.S. investors in this tech leader, today, Dec. 19, 2025.NYSE : INFYInfosysToday's Change( 5.42 %) $ 1.04Current Price$ 20.22Key Data PointsMarket Cap$80BDay's Range$ 18.99 - $ 30.0052wk Range$ 15.81 - $ 30.00Volume119MAvg Vol14MGross Margin30.53 %Dividend Yield2.69 %Infosys (INFY +5.42%), provides consulting, technology, outsourcing, and digital services globally. Infosys IPO'ed in 1999 and has grown 3,362% since going public. Bas ...

Accenture's EPS for the quarter ending November 2025 is projected to be $3.74, a 4.2% increase year-over-year.Revenue is anticipated to reach $18.56 billion, marking a 4.9% rise from the previous year.The company's financial metrics indicate a P/E ratio of approximately 22.06 and a debt-to-equity ratio of 0.26.Accenture (NYSE:ACN) is a global professional services company that provides a wide range of services in strategy, consulting, digital, technology, and operations. It competes with other major consult ...

Group 1 - Premier has been acquired by Patient Square Capital and will operate as a wholly owned subsidiary, with its board resigning under the purchase agreement [3][7] - The acquisition was valued at $2.6 billion, with Premier stockholders receiving $28.25 in cash per share, and the deal closed earlier than anticipated [7] - Premier's revenue for the quarter ended September 30 was reported at $240 million, a decrease of 3% year over year, while net income from continuing operations fell by 79% to $15.3 million [4] Group 2 - The acquisition follows Premier's exploration of strategic alternatives, including a potential sale, due to declining stock prices and financial challenges [4] - Premier has divested some assets, including its non-healthcare GPO operations and is winding down its employee health benefits subsidiary, Contigo Health [5] - Patient Square's portfolio includes other healthcare firms such as ChenMed, Access Telecare, and CorroHealth, indicating a focus on value-based care and revenue cycle management [5]

Core Insights - Matrix Asset Advisors reported a recovery in the stock market with a gain of +8.12% in Q3 2025 and +14.83% year-to-date [1] - The Matrix Large Cap Value strategy outperformed both the S&P 500® and the Russell 1000 Value® Index in Q3 2025 [1] - The Matrix Dividend Income (MDI) portfolio showed robust performance over the nine months ending September 30, with gains in the low teens [1] Company Analysis: Accenture plc (NYSE:ACN) - Accenture plc experienced a one-month return of -2.77% and a 52-week decline of 32.86%, closing at $240.79 with a market cap of $149.977 billion on November 20, 2025 [2] - The decline in Accenture's stock is attributed to a slowdown in client spending and reduced forward bookings, along with delays and cancellations in government contracts, which constitute about 8% of its revenue [3] - Despite current challenges, Accenture projects earnings growth of 5% to 8% for 2026 and has a strong balance sheet with more cash than debt, expecting to generate close to $10 billion in free cash flow this year [3] - Accenture raised its dividend by 10%, increasing its yield to 2.7%, and authorized a $5 billion share repurchase program [3] - In Q4 2025, Accenture reported revenues of $17.6 billion, reflecting a 7% increase in U.S. dollars and 4.5% in local currency [4]

Core Points - Rasmussen University has formed a corporate alliance with Hilton Grand Vacations (HGV) to provide educational benefits to HGV team members, including up to 100% tuition coverage for select online programs [1][3] - The alliance aims to enhance career growth opportunities for HGV employees by reducing financial barriers to education [3][4] - Eligible HGV team members can also receive up to a 20% tuition reduction for other qualified programs at Rasmussen University [2] Company Overview - Rasmussen University is an accredited institution committed to providing innovative, career-ready higher education and healthcare education, with a history of 125 years in transforming lives and strengthening communities [7][9] - The university offers a range of undergraduate and graduate programs both online and in-person across 20 campuses in the U.S. [7] Educational Programs - The programs offered by Rasmussen University are designed to help working adults advance their skills and careers through flexible, career-focused education [3][6] - The curriculum is developed with input from industry professionals, ensuring relevance to current job market needs [6] Employee Development - HGV emphasizes the importance of personal and professional growth for its team members, and the partnership with Rasmussen University is seen as a way to enhance employee development and retention [3][4] - The alliance is expected to attract significant interest from HGV employees, indicating a strong demand for educational opportunities [3]

Core Insights - Health Catalyst (HCAT) is expected to report quarterly earnings of $0.05 per share, reflecting a year-over-year decline of 28.6% [1] - Revenue projections stand at $75.08 million, indicating a decrease of 1.7% compared to the same quarter last year [1] - The consensus EPS estimate has remained unchanged over the last 30 days, suggesting analysts have reevaluated their initial estimates [1][2] Revenue Estimates - Analysts predict 'Revenue- Professional services' will reach $23.08 million, a decline of 16.7% from the prior-year quarter [4] - 'Revenue- Technology' is estimated at $52.00 million, showing a year-over-year increase of 6.9% [4] Profit Estimates - The average prediction for 'Adjusted Gross Profit- Professional Services' is $4.45 million, down from $4.72 million reported in the same quarter last year [5] - The consensus estimate for 'Adjusted Gross Profit- Technology' is $34.90 million, compared to $31.57 million reported in the same quarter last year [5] Stock Performance - Health Catalyst shares have increased by 7% over the past month, outperforming the Zacks S&P 500 composite, which rose by 1.3% [5] - The company holds a Zacks Rank 3 (Hold), indicating it is expected to closely follow overall market performance in the near term [5]

Core Insights - SLB N.V. is a leading global oil-field services company with a market capitalization of $53.9 billion [1] Stock Performance - SLB stock has underperformed the broader market, declining 6% year-to-date and 10.2% over the past 52 weeks, while the S&P 500 Index increased by 6.3% in 2025 and 17.7% over the past year [2] - The stock has also lagged behind the Energy Select Sector SPDR Fund's 2.9% increase in 2025 and marginal gains over the past 52 weeks [3] Market Outlook - The company has indicated a downturn in upstream spending, particularly in North and Latin America, negatively impacting its outlook [4] - A soft commodity price environment, macroeconomic challenges, and weak exploration budgets have reduced demand for oil-field services, which is SLB's core business [4] Earnings Expectations - For fiscal 2025, analysts expect SLB to report an EPS of $2.89, reflecting a 15.3% year-over-year decline [5] - The company has a mixed earnings surprise history, missing bottom-line estimates once in the past four quarters but surpassing projections three times [5] Analyst Ratings - The stock holds a consensus "Strong Buy" rating, with 16 "Strong Buys," four "Moderate Buys," and three "Holds" among 23 analysts [5] - Rothschild Redburn recently initiated coverage on SLB with a "Buy" rating and a $48 price target, highlighting SLB's strategic shift towards less cyclical businesses [6] Price Targets - SLB's mean price target of $46.68 indicates a 29.5% premium to current price levels, while the highest target of $82 suggests a potential upside of 127.4% [7]